Presentation is loading. Please wait.

Presentation is loading. Please wait.

SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved.

Published byMarianna Betty Jennings Modified over 9 years ago

Similar presentations

Presentation on theme: "SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved."— Presentation transcript:

1 SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved.

2 SLIT and Atopic Dermatitis SLIT has been poorly studied in pediatric AD Results mixed: 2 open-controlled studies with improvement Mastrandrea, F; Sergio G et al: Specific sublingual immunotherapy in atopic dermatitis. Allergol Immunopathol 28:54-62, 2000 Petrova, SI; Berzhets, VM et al: Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites. Zh Mikrobiol Immunobiol 1:33-36, 2001. 1 open-controlled study without improvement Galli, E; Chini, L et al: Use of oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 22:18-24, 1994 ©2008 Allergychoices, Inc. All Rights Reserved.

3 SLIT and Atopic Dermatitis ©2007 Allergychoices, Inc. All Rights Reserved.

4 Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007. ©2008 Allergychoices, Inc. All Rights Reserved. Study Design 56 children Ages 5-16 yrs 1 month observ SCORAD classified HDM +spt, RAST SLIT (28) Placebo (28) 2 dropouts: Systemic rxn 6 dropouts: 1 moved 3 noncompliant 2 lost to f/u 26 SLIT 22 Placebo 14 mild-mod AD 12 severe AD 18 month f/u SCORAD VAS Med Rescue

5 Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007. ©2008 Allergychoices, Inc. All Rights Reserved. 100 RAST U/ml #drops 1 drop = 50ul 1 2 3 4 5 1000 RAST u/ml10,000 RAST u/ml 1 2 3 4 5 1 2 3 4 5 15 day buildup Maintenance 5 drops 3x/wk For 18 mos (24/26 pts)

6 Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007. ©2008 Allergychoices, Inc. All Rights Reserved. Caculations for monthly Der p1 & Der f1 dosing : 5 drops 3x/wk = 15 drops/wk x 4 weeks = 60 drops/month 1 drop = 50 uL 60 drops = 3000 ul = 3 ml/month High concentration vial = 4.3ug/ml Der p1, 3.5 ug/ml Der fl 1 month = 3x 4.3 ug/ml Der p1 = 12.9 ug Der p1/month 1 month = 3ml x 3.5 ug/ml Der f1 = 10.5 ug Der f1/month SLIT/SCIT ratio approximately 9

7 ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007.

8 ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007.

9 ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007.

10 ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007.

11 ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007.

12 SCORAD ImprovVAS improvRescue Med improv All ADP=.0025*NSP=.03* Mild/Mod ADP<.0005*P=.002*P=.01* Severe ADNS ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007 Clinical Efficacy: Parameter Measurements

13 Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007. ©2008 Allergychoices, Inc. All Rights Reserved. Side EffectSLITPlacebo Fatigue61 Headache1- Local ENT swelling during buildup phase 4- Adverse Events (2 patients dropped out of Rx group due to Generalized itching and skin flareup on SLIT)

14 Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007. ©2008 Allergychoices, Inc. All Rights Reserved. “…We conclude that SLIT with a standardized mite extract can be considered effective in children with mild- moderate Allergic AD, whereas the benefit was inconsistent in the severe form…”

15 Question: Were the results biased against improvement because of: Infrequent use (3x/wk SLIT) Total load effect: 5 active/2 placebo had concomitant pollen sensitization ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007

16 Questions for the future… SLIT for AD in adult patients? SLIT for AD with other inhalant allergens? SLIT for AD with food allergens? SLIT for AD with inhalant and food allergens? SLIT for other skin diseases?: urticaria from inhalants and/or foods? Contact dermatitis? ©2008 Allergychoices, Inc. All Rights Reserved. Pajno, Caminiti et al: SLIT in mite-sensitized children with AD: A randomized, double-blind, placebo controlled study. JACI 120: 164-170, 2007

Download ppt "SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved."

Similar presentations

Decreasing the burden of allergy

Decreasing the burden of allergy
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.

Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Food Allergy Update Thomas Flaim, M.D.. Prevalence of Food Allergy Prevalence rate is 6% in children < 3 years of age; 4% in adults Prevalence rate is.

Food Allergy Update Thomas Flaim, M.D.. Prevalence of Food Allergy Prevalence rate is 6% in children < 3 years of age; 4% in adults Prevalence rate is.
GIRISH VITALPUR, MD, FAAP, FAAAAI ASSISTANT PROFESSOR OF CLINICAL PEDIATRICS, RILEY CHILDREN’S HOSPITAL, INDIANA UNIVERSITY SCHOOL OF MEDICINE, INDIANAPOLIS,

GIRISH VITALPUR, MD, FAAP, FAAAAI ASSISTANT PROFESSOR OF CLINICAL PEDIATRICS, RILEY CHILDREN’S HOSPITAL, INDIANA UNIVERSITY SCHOOL OF MEDICINE, INDIANAPOLIS,
Bret Haymore, MD FAAAAI, FACAAI

Bret Haymore, MD FAAAAI, FACAAI
Food Allergy Highlights of the past 3 years Adam Fox Paediatric Study Day Cheltenham June 2004 Dr Adam Fox.

Food Allergy Highlights of the past 3 years Adam Fox Paediatric Study Day Cheltenham June 2004 Dr Adam Fox.
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.

Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
Dr Narayana pradeep Consultant Pulmonologist Carewell hospital KasaragodKERALA.

Dr Narayana pradeep Consultant Pulmonologist Carewell hospital KasaragodKERALA.
By Jacqueline Wivinus and Kristina Hegarty.  Objective: To study the effects of the use of probiotics in pediatric patients that suffer from atopic dermatitis.

By Jacqueline Wivinus and Kristina Hegarty.  Objective: To study the effects of the use of probiotics in pediatric patients that suffer from atopic dermatitis.
Introduction to Food Allergens

Introduction to Food Allergens
A randomized, double-blind study on MD-knee versus HA in patients affected by knee OA: preliminary data from the JOINT study Umberto Massafra Dep of Rheumatology,

A randomized, double-blind study on MD-knee versus HA in patients affected by knee OA: preliminary data from the JOINT study Umberto Massafra Dep of Rheumatology,
Agency for Healthcare Research and Quality (AHRQ)

Agency for Healthcare Research and Quality (AHRQ)
Use of Multiple Allergen Mixes in Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Denver School.

Use of Multiple Allergen Mixes in Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Denver School.
Main difference: time required to reach maintenance dose.

Main difference: time required to reach maintenance dose.
ATOPY. What is Atopic? Atopic syndrome is an allergic affecting parts of the body not in direct contact with the allergen. The origin of atopy.

ATOPY. What is Atopic? Atopic syndrome is an allergic affecting parts of the body not in direct contact with the allergen. The origin of atopy.
T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.

T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.
The spectrum of allergic diseases Hugo Van Bever Department of Pediatrics National University Singapore APAPARI workshop – Hanoi, Vietnam – May 2008.

The spectrum of allergic diseases Hugo Van Bever Department of Pediatrics National University Singapore APAPARI workshop – Hanoi, Vietnam – May 2008.
Trigger factors Difference between trigger and cause.

Trigger factors Difference between trigger and cause.
Anti-IgE in Asthma and Other Allergic Diseases Harold S. Nelson. MD Professor of Medicine National Jewish Health And University of Colorado School of Medicine.

Anti-IgE in Asthma and Other Allergic Diseases Harold S. Nelson. MD Professor of Medicine National Jewish Health And University of Colorado School of Medicine.
SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.

SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.

Similar presentations

Ads by Google